Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Characterization of the plasma proteome of multiple myeloma and its precursor conditions and identification of a prognostic high-risk signature of progression

Blood (2025) 146 (Supplement 1): 2168.

https://doi.org/10.1182/blood-2025-2168

Published: 2025

Journal Articles

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

Blood (2025) 146 (Supplement 1): 1533.

https://doi.org/10.1182/blood-2025-1533

Published: 2025

Journal Articles

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Blood (2025) 146 (Supplement 1): 921.

https://doi.org/10.1182/blood-2025-921

Published: 2025

Journal Articles

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Blood (2025) 146 (Supplement 1): 582.

https://doi.org/10.1182/blood-2025-582

Published: 2025

Journal Articles

Treatment response, relapse and survival of hospitalized adult primary warm autoimmune hemolytic anemia: A multicenter retrospective cohort study

Wenru Yue, Meng Shu, Sijia Dong, Jia Shao, Yihan Liu, Xiaoqin Wang, Ting Wu

Blood (2025) 146 (Supplement 1): 4656.

https://doi.org/10.1182/blood-2025-4656

Published: 2025

Journal Articles

Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+

Blood (2025) 146 (1): 89–103.

https://doi.org/10.1182/blood.2024025102

Published: 2025

Includes: Supplemental data

Journal Articles

Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression

Blood (2024) 144 (Supplement 1): 1903.

https://doi.org/10.1182/blood-2024-209286

Published: 2024

Journal Articles

Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Blood (2024) 144 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2024-206540

Published: 2024

Journal Articles

IGF2BP1 Orchestrates Post-Transcriptional Control of Globin Switching through Direct Binding to Globins and Their Regulators

Steven Coyne, Ting Wu, Divya Vinjamur, Mir Hossain, Daniel E. Bauer

Blood (2024) 144 (Supplement 1): 414.

https://doi.org/10.1182/blood-2024-210473

Published: 2024

Journal Articles

Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma

Nayda Bidikian, Francesco Corrado, Romanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Rosa Toenges, Jean-Baptiste Alberge, Michelle P. Aranha, Ting Wu, Michael Timonian, Shonali Midha, Elizabeth K. O'Donnell, Yuxin Liu, Sophie Magidson, Ashlee Strutevant, Kenneth C. Anderson, Nikhil C. Munshi, Omar Nadeem, Gad Getz, Irene Ghobrial

Blood (2024) 144 (Supplement 1): 488.

https://doi.org/10.1182/blood-2024-207299

Published: 2024

Journal Articles

Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control

Romanos Sklavenitis-Pistofidis, Ting Wu, Elizabeth D. Lightbody, Yoshinobu Konishi, Mahshid Rahmat, Michael P. Agius, Junko Tsuji, Jean-Baptiste Alberge, Michael Timonian, Ankit K. Dutta, Michelle P. Aranha, Nayda Bidikian, Hadley Barr, Nicholas J. Haradhvala, Moshe Sade-Feldman, Gad Getz, Irene Ghobrial

Blood (2024) 144 (Supplement 1): 1895.

https://doi.org/10.1182/blood-2024-208837

Published: 2024

Journal Articles

Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1928.

https://doi.org/10.1182/blood-2024-203684

Published: 2024

Journal Articles

Single-Cell RNA Sequencing of Circulating Tumor Cells in Precursor Myeloma Patients Reveals Mechanisms of Disease Dissemination

Blood (2023) 142 (Supplement 1): 872.

https://doi.org/10.1182/blood-2023-189760

Published: 2023

Journal Articles

Single-Cell RNA Sequencing Reveals Hypo-Responsiveness of T and NK Cells to Interferon Stimulation As an Immune Hallmark in Asymptomatic Waldenstrom's Macroglobulinemia

Yoshinobu Konishi, Romanos Sklavenitis-Pistofidis, Daniel L. Mallory, Ting Wu, Michelle P. Aranha, Junko Tsuji, Nicholas J Haradhvala, Elizabeth D. Lightbody, Katherine Towle, Laura Hevenor, Nickolas Tsakmaklis, Xiyue Wang, Alexa G Canning, Christine-Ivy Liacos, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Steven P Treon, Gady Getz, Irene M. Ghobrial

Blood (2023) 142 (Supplement 1): 2026.

https://doi.org/10.1182/blood-2023-186470

Published: 2023

Journal Articles

Preclinical Study of DZD8586, a Non-Covalent LYN/BTK Dual Inhibitor with Excellent BBB Penetration, for the Treatment of B-Cell Non-Hodgkin Lymphoma (B-NHL)

Yu Bai, Ting Wu, Minghui Hu, Sufang Han, Yu Liu, Jie Zheng, Junjun Qin, Lin Zhang, Zhenfan Yang

Blood (2023) 142 (Supplement 1): 2822.

https://doi.org/10.1182/blood-2023-185156

Published: 2023

Journal Articles

Large-Scale Characterization and Functional Assessment of Adaptive Immunity in Patients with MGUS and SMM Reveals Significant Defects

Blood (2023) 142 (Supplement 1): 2548.

https://doi.org/10.1182/blood-2023-178062

Published: 2023

Journal Articles

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy

Romanos Sklavenitis-Pistofidis, Michelle P. Aranha, Nicholas J. Haradhvala, Shohreh Varmeh, Daniel Heilpern-Mallory, Ting Wu, Nang Kham Su, Elizabeth D. Lightbody, François Aguet, Oksana Zavidij, Sabrin Tahri, Tarek H. Mouhieddine, Gad Getz, Irene Ghobrial

Blood (2022) 140 (Supplement 1): 268–269.

https://doi.org/10.1182/blood-2022-168839

Published: 2022

Journal Articles

Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology

Blood (2022) 140 (Supplement 1): 254–255.

https://doi.org/10.1182/blood-2022-167325

Published: 2022

Journal Articles

Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM

Blood (2022) 140 (Supplement 1): 7158–7159.

https://doi.org/10.1182/blood-2022-167212

Published: 2022

Journal Articles

Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells

Romanos Sklavenitis-Pistofidis, Ting Wu, Mahshid Rahmat, Yoshinobu Konishi, Elizabeth D. Lightbody, Michael Timonian, Junko Tsuji, Danielle T. Firer, Nicholas J. Haradhvala, Cinnie Yentia Soekojo, Xiyue Wang, Daniel Heilpern-Mallory, François Aguet, Gad Getz, Irene Ghobrial

Blood (2022) 140 (Supplement 1): 860–861.

https://doi.org/10.1182/blood-2022-168911

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Characterization of the plasma proteome of multiple myeloma and its precursor conditions and identification of a prognostic high-risk signature of progression

Results of the Phase II d-PRISM study: Daratumumab in high-risk MGUS and low-risk smoldering myeloma

Single-cell immune profiling reveals enhanced immune fitness of endogenous and engineered T cells in patients with high-risk smoldering myeloma compared to Relapsed/Refractory myeloma following bispecific antibodies or CAR-T cell therapies.

Monoclonal gammopathy of indeterminate potential (MGIP) as a stable premalignant entity preceding hematologic malignancy

Treatment response, relapse and survival of hospitalized adult primary warm autoimmune hemolytic anemia: A multicenter retrospective cohort study

Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+

Comprehensive Characterization of the Plasma Proteome of Multiple Myeloma and Its Precursor Conditions and Identification of a Proteomic Signature to Improve Risk Prediction of Disease Progression

Single-Cell Profiling of ~1.7 Million Plasma Cells across >250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

IGF2BP1 Orchestrates Post-Transcriptional Control of Globin Switching through Direct Binding to Globins and Their Regulators

Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma

Single-Cell RNA-Sequencing of 6 Million Tumor and Immune Cells in 365 Patients with MGUS and SMM Demonstrates Complex Progressive Changes in Immune Cell Functionality with a Distinct Footprint on Tumor Cell Biology and Disease Control

Tumor-Intrinsic and Immune Predictors of Response to Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Single-Cell RNA Sequencing of Circulating Tumor Cells in Precursor Myeloma Patients Reveals Mechanisms of Disease Dissemination

Single-Cell RNA Sequencing Reveals Hypo-Responsiveness of T and NK Cells to Interferon Stimulation As an Immune Hallmark in Asymptomatic Waldenstrom's Macroglobulinemia

Preclinical Study of DZD8586, a Non-Covalent LYN/BTK Dual Inhibitor with Excellent BBB Penetration, for the Treatment of B-Cell Non-Hodgkin Lymphoma (B-NHL)

Large-Scale Characterization and Functional Assessment of Adaptive Immunity in Patients with MGUS and SMM Reveals Significant Defects

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy

Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology

Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM

Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only